Clinical Trials on Hepatic Impairment in United States

Total 2290 results

Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

Healthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Moderate Hepatic Impairment | Normal Hepatic Function

United States
Takeda

Completed

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

Severe Hepatic Impairment

United States
Pfizer

Completed

Evaluate Severe Hepatic Impairment on Dacomitinib PK

Severe Hepatic Impairment

United States
Bausch Health Americas, Inc.

Terminated

Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

Severe Hepatic Impairment

United States
Agios Pharmaceuticals, Inc.

Completed

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

Moderate Hepatic Impairment

United States
Shire

Completed

Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

Hepatic Impairment

United States
Merck Sharp & Dohme LLC

Completed

Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020)

Moderate Hepatic Impairment

United States
KBP Biosciences
Covance

Completed

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

Healthy | Moderate Hepatic Impairment

United States
Jazz Pharmaceuticals

Completed

Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

Hepatic Impairment

United States
EQRx International, Inc.

Completed

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Severe Hepatic Impairment

United States
Genfit

Completed

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Liver Diseases | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
Seagen Inc.

Completed

A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects

Hepatic Impairment

United States
Atea Pharmaceuticals, Inc.

Recruiting

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment | Healthy Volunteer

United States
Daiichi Sankyo, Inc.

Completed

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

Moderate Hepatic Impairment

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Mild and Moderate Hepatic Impairment

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

Healthy | Hepatic Impairment

United States
Nektar Therapeutics

Completed

A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

Hepatic Impairment | Normal Hepatic Function

United States
Eisai Inc.

Completed

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

Hepatic Impairment | Hepatic Function

United States
Novartis Pharmaceuticals

Completed

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

Normal Hepatic Function | Impaired Hepatic Function

United States
Daiichi Sankyo, Inc.

Completed

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

Hepatic Impairment | Moderate Impaired Hepatic Function

United States
Biotie Therapies Inc.
Acorda Therapeutics

Terminated

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Hepatic Impairment

United States
Acerta Pharma BV
AstraZeneca

Completed

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Hepatic Insufficiency | Healthy Subjects | Hepatic Impairment

United States
Basilea Pharmaceutica

Active, not recruiting

A Clinical Trial of the Study Medicine (Called Fosmanogepix) in People With Hepatic Dysfunction.

Hepatic Impairment

United States
Galmed Research and Development, Ltd.

Enrolling by invitation

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Hutchmed

Completed

Fruquintinib Hepatic Impairment Study

Hepatic Impairment

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Tepotinib Hepatic Impairment Trial

Hepatic Impairment

United States
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Hepatic Impairment

United States
Pfizer

Completed

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib

Hepatic Impairment

United States
Intercept Pharmaceuticals

Completed

Hepatic Impairment Trial of Obeticholic Acid

Hepatic Impairment

United States
Portola Pharmaceuticals

Completed

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Hepatic Impairment

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Cephalon

Completed

A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment

Hepatic Impairment

United States
Alkermes, Inc.

Completed

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
Wockhardt

Completed

Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

Hepatic Impairment

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

Hepatic Impairment

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Hepatic Impairment

Hepatic Impairment

United States
Melinta Therapeutics, Inc.

Completed

Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

Hepatic Impairment

United States
Biogen

Completed

BG9928 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Institut de Recherches Internationales Servier

Completed

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

Hepatic Impairment

United States
Pfizer

Completed

Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Allergan

Completed

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

Hepatic Impairment

United States
PTC Therapeutics

Completed

A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics

Hepatic Impairment

United States

3

Subscribe